Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.
Departments of *Clinical Sciences †Laboratory Medicine ‡Experimental Medical Science, Lund University, Lund, Sweden §Department of Neuroscience, CNS and Pain, AstraZeneca R&D, Södertälje, Sweden ‖Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden ¶Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom **Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Ulf
U
Karlsson
Johanna
J
Repits
Liselotte
L
Antonsson
Erik
E
Cederfjäll
Bengt
B
Ljungberg
Martin
M
Ålenius
Alan
A
Sabirsh
Magnus
M
Gisslen
Joakim
J
Esbjörnsson
Marianne
M
Jansson
D000163:Acquired Immunodeficiency Syndrome / Q000821:virology*; D065100:CCR5 Receptor Antagonists / Q000494:pharmacology*; D003510:Cyclohexanes / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D009154:Mutation; D014230:Triazoles / Q000494:pharmacology*; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000378:metabolism
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D014230:Triazoles; D054299:env Gene Products, Human Immunodeficiency Virus; D000077592:Maraviroc